Nurix Therapeutics, Inc. Financials

Market Capitalization $970.5 Million as of July 1, 2025

Valuations Metrics as of Jul. 5, 2025

Trailing PE
Forward PE	-4.58
Price to Sales TTM	$17.20
Price to Book MRQ	$2.02
Enterprise to Revenue	6.12
Enterprise to EBITDA	-1.55

Financial Reports as of Feb. 28, 2025

Financials

Fiscal Year Ends	2024-11-30
Most Recent Quarter	2025-02-28
Profit Margin	0.00%
Operating Margin	-340.67%
Return on Assets TTM	-31.08%
Return on Equity TTM	-64.16%

Income Statement

Revenue TTM	$56,417,000
Revenue per Share TTM	$0.76
Quarterly Revenue Growth	11.30%
Gross Profit TTM	$-184,872,992
EBITDA	$-222,348,992
Net Income to Common TTM	$-208,402,000
Diluted EPS TTM	$-2.79
Quarterly Earnings Growth YoY	11.26%

Balance Sheet

Total Cash MRQ	$549,680,000
Total Cash per Share MRQ	$7.21
Total Debt MRQ	$
Total Debt to Equity MRQ	5.54
Current Ratio MRQ	6.26
Book Value per Share MRQ	$6.31

Cash Flow

Operating Cash Flow TTM	$-191,720,000
Levered Free Cash Flow TTM	$-106,558,000

NRIX Stock Info as of Jul. 5, 2025

Stock Statistics

Shares Outstanding	75,870,718
Float Shares	57,748,462
Avg 10 Volume	788,970
Avg 30 Volume	None
Shares Short	14,435,008
Short Ratio	17.31
Short % of Shares	22.25%
% Held by Insiders	1.41%
% Held by Institutions	111.85%

Stock Price Summary

Beta	2.16
Fifty Two Week Low	$8.18
Fifty Two Week High	$29.56
Fifty Two Week Change	-61.04%
Day 50 MA	$11.13
Day 200 MA	$17.22

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date